PULMOZYME 2500U / 2.5ml inhalation solution by nebulization medication leaflet

R05CB13 dornase alfa • Respiratory system | Expectorants, excl. combinations with cough suppressants | Mucolytics

Dornaza alfa is a medication used for the treatment of cystic fibrosis. It is a recombinant enzyme that breaks down DNA in the thick mucus accumulated in the lungs, facilitating its clearance and improving respiratory function.

The medication is administered via inhalation, usually once daily, using a nebulizer. It is effective in reducing the frequency of respiratory infections and alleviating respiratory symptoms.

Side effects may include sore throat, hoarseness, skin rash, and, in rare cases, severe allergic reactions. Regular monitoring is essential to assess treatment effectiveness.

Consult your doctor to discuss the benefits and risks of treatment with Dornaza alfa. Follow the usage instructions to ensure therapy effectiveness.

General data about PULMOZYME 2500U / 2.5ml

Substance: dornase alfa

Date of last drug list: 01-06-2025

Commercial code: W61214001

Concentration: 2500U / 2.5ml

Pharmaceutical form: inhalation solution by nebulization

Packing volume: 2,5 ml

Product type: original

Price: 539.47 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: ROCHE PHARMA AG - GERMANIA

Holder: ROCHE ROMANIA S.R.L. - ROMANIA

Number: 6524/2014/01

Shelf life: 2 years

Pharmaceutical forms available for dornase alfa

Concentrations available for dornase alfa

1mg/ml, 2500U/2.5ml

Compensation lists for PULMOZYME 2500U / 2.5ml ROCHE

NHP 6.4 (C2) - Cystic fibrosis

Price

Copayment

Patient

539.47 RON

539.47 RON

0.00 RON

NHP 9.1 (C2) - Spinal cord transplant

Price

Copayment

Patient

539.47 RON

539.47 RON

0.00 RON